ରେମଡେସିଭିର
Clinical data | |
---|---|
Pronunciation | /rɛmˈdɛsɪvɪər/ REM-DESS-I-veer |
Trade names | Veklury |
Synonyms | GS-5734 |
AHFS/Drugs.com | monograph |
MedlinePlus | a620033 |
data |
|
Pregnancy category | |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
ECHA InfoCard | 100.302.974 |
Chemical and physical data | |
Formula | C27H35N6O8P |
Molar mass | ୬୦୨.୫୮ g·mol−1 |
3D model (JSmol) | |
| |
|
ରେମଡେସିଭିର, ବ୍ରାଣ୍ଡ ନାମ ଭେକ୍ଲୁରି, ଏକ ଭୂତାଣୂରୋଧୀ ଔଷଧ ଯାହା ଅମ୍ଳଜାନ ଚିକିତ୍ସା ଆବଶ୍ୟକ କରୁଥିବା କିମ୍ବା ଅଧିକ ବିପଦ ପୂର୍ଣ୍ଣ କୋଭିଡ-୧୯ ରୋଗ ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।[୧୧] [୧୨] ନଭେମ୍ବର ୨୦୨୦ ମସିହାରେ ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନ ଏହି ରୋଗ ଚିକିତ୍ସା ନିମନ୍ତେ ସର୍ତ୍ତମୂଳକ ସୁପାରିଶ କରିଥିଲା | ଏହା ଶିରାଭ୍ୟନ୍ତର ଇଞ୍ଜେକସନ ଆକାରରେ ୩ରୁ ୧୦ ଦିନ ପର୍ଯ୍ୟନ୍ତ ଦିଆଯାଏ ।[୧୩] [୧୪]
ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅଧିକ ଯକୃତ ଏଞ୍ଜାଇମ ନିର୍ଗତ ହୁଏ ଏବଂ ଅଇ ଉଠିଥାଏ | [୧୩] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଆଲର୍ଜି ହୋଇପାରେ | [୧୫] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର ନିରାପଦ କି ନୁହେଁ ତାହା ଅସ୍ପଷ୍ଟ; ଯଦିଓ ସ୍ତନ୍ୟପାନରେ ନିରାପଦ ଅଛି | [୧୬] ଶରୀର ଭିତରେ ରେମଡେସିଭିର ରୁପାନ୍ତର ହୋଇ ଜିଏସ-୪୪୧୫୨୪ ଟ୍ରାଇଫସଫେଟରେ ପରିଣତ ହୋଇଥାଏ ଯାହା ଭୂତାଣୁ ଆରଏନଏ ପଲିମରେଜର ଏକ ରାଇବୋନିଉକ୍ଲିଓଟାଇଡ ଅନାଲଗ ଇନହିବିଟର ।[୧୭]
ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଅକ୍ଟୋବର ୨୦୨୦ ମସିହାରେ ଆମେରିକାରେ ଓ ଜୁଲାଇ ୨୦୨୦ ମସିହାରେ ୟୁରୋପରେ ଅନୁମୋଦିତ ହୋଇଥିଲା [୧୨] [୧୮] ଏହା ଗିଲିଡ ବିଜ୍ଞାନ କମ୍ପାନୀଦ୍ୱାରା ବିକଶିତ ହୋଇଥିଲା ଯାହା ମୂଳତଃ ହେପାଟାଇଟିସ ସି, ଇବୋଲା ଭୂତାଣୁ ରୋଗ, ଏବଂ ମାରବର୍ଗ ଭୂତାଣୁ ରୋଗ ଚିକିତ୍ସା ନିମନ୍ତେ ଅନୁଶୀଳନ କରାଯାଇଥିଲା ।[୧୯] [୨୦] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୧ ମସିହା ସୁଦ୍ଧା ପାଞ୍ଚ ଦିନ ପାଇଁ ଏହାର ମୂଲ୍ୟ ପ୍ରାୟ ୨,୬୦୦ ଡଲାର ଥିଲା | [୨୧] ବ୍ରିଟେନରେ ଏହି ରାଶି ପ୍ରାୟ ୨,୦୪୦ ପାଉଣ୍ଡ ଅଟେ | [୨୨]
ଆଧାର
ସମ୍ପାଦନା- ↑ ୧.୦ ୧.୧ "Veklury Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 13 July 2020. Archived from the original on 13 August 2020. Retrieved 16 August 2020.
- ↑ "Veklury Powder for Injection Product Information". Therapeutic Goods Administration (TGA). 9 June 2021. Retrieved 16 August 2020.
- ↑ "Veklury remdesivir 100 mg powder for injection vial". Therapeutic Goods Administration (TGA). Archived from the original on 23 October 2021. Retrieved 22 October 2021.
- ↑ "COVID-19 treatment: Gilead Sciences Pty Ltd, remdesivir (Veklury)". Therapeutic Goods Administration (TGA). 10 July 2020. Archived from the original on 21 October 2021. Retrieved 22 October 2021.
- ↑ "Veklury Product information". Health Canada. 25 April 2012. Archived from the original on 26 October 2020. Retrieved 22 October 2020.
- ↑ ଆଧାର ଭୁଲ: ଅଚଳ
<ref>
ଚିହ୍ନ;Veklury EPAR
ନାମରେ ଥିବା ଆଧାର ଭିତରେ କିଛି ଲେଖା ନାହିଁ । - ↑ "Veklury 100 mg concentrate for solution for infusion – Summary of Product Characteristics (SmPC)". (emc). 6 July 2020. Archived from the original on 24 November 2020. Retrieved 4 October 2020.
- ↑ "Veklury 100 mg powder for concentrate for solution for infusion – Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 8 October 2020. Retrieved 4 October 2020.
- ↑ "Remdesivir injection Remdesivir injection, powder, lyophilized, for solution". DailyMed. 1 September 2020. Archived from the original on 26 September 2020. Retrieved 25 September 2020.
- ↑ ଆଧାର ଭୁଲ: ଅଚଳ
<ref>
ଚିହ୍ନ;FDA PR 20201022
ନାମରେ ଥିବା ଆଧାର ଭିତରେ କିଛି ଲେଖା ନାହିଁ । - ↑ "Remdesivir Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 13 July 2021.
- ↑ ୧୨.୦ ୧୨.୧ "Veklury EPAR". European Medicines Agency (EMA). 23 June 2020. Retrieved 6 July 2020.
- ↑ ୧୩.୦ ୧୩.୧ "Remdesivir Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 13 July 2021.
- ↑ "Statement on Therapies for High-Risk, Nonhospitalized Patients". COVID-19 Treatment Guidelines (in ଇଂରାଜୀ). Archived from the original on 7 January 2022. Retrieved 7 January 2022.
- ↑ "Fact Sheet for Patients And Parent/Caregivers Emergency Use Authorization (EUA) Of Remdesivir For Coronavirus Disease 2019 (COVID-19)" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 8 May 2020.
- ↑ "Remdesivir (Veklury) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Retrieved 13 July 2021.
- ↑ Yan, Victoria C.; Muller, Florian L. (14 May 2020). "Gilead should ditch remdesivir and focus on its simpler and safer ancestor". Stat. Boston Globe Media Partners.
- ↑ "New Drug Therapy Approvals 2020". U.S. Food and Drug Administration (FDA). 31 December 2020. Retrieved 17 January 2021.
- ↑ Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, Berrino L, Racagni G, Rossi F, Capuano A (April 2020). "Current pharmacological treatments for COVID-19: What's next?". British Journal of Pharmacology. 177 (21): 4813–4824. doi:10.1111/bph.15072. eISSN 1476-5381. PMC 7264618. PMID 32329520.
{{cite journal}}
: Unknown parameter|displayauthors=
ignored (|display-authors=
suggested) (help) - ↑ Stephens, Bret (18 April 2020). "The Story of Remdesivir". The New York Times. p. A23. Retrieved 11 May 2020.
- ↑ Chamary, J. V. "The Strange Story Of Remdesivir, A Covid Drug That Doesn't Work". Forbes (in ଇଂରାଜୀ). Retrieved 13 July 2021.
- ↑ "6.1. Coronavirus". British National Formulary (BNF) (82 ed.). BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. pp. 665–667. ISBN 978-0-85711-413-6.
{{cite book}}
: CS1 maint: date format (link)